Sinclair
- Consolidated Income Statement
- Balance Sheet
- Statement of Changes in Shareholders' Equity
- Cash Flow Statements
- Notes to the Financial Statements
- 1. General information
- 2. Accounting Policies
- 3. Financial risk management
- 4. Segmental information
- 5. Exceptional operating items
- 6. Expenses by nature
- 7. Employees and Directors
- 8. Finance Income and costs
- 9. Taxation on loss on ordinary activities
- 10. Loss for the financial year
- 11. Loss per share
- 12. Goodwill
- 13. Intangible asssets
- 14. Property, plant and equipment
- 15. Investments
- 16. Deferred tax asset
- 17. Inventories
- 18. Trade and other receivables
- 19. Trade and other payables
- 20. Borrowings
- 21. Provisions
- 22. Financial instruments
- 23. Called-up share capital
- 24. Share premium
- 25. Options and warrants over shares of Sinclair Pharma plc
- 26. Share based payments
- 27. Other Reserves
- 28. Cash flows from operating activities
- 29. Operating lease commitments
- 30. Capital commitments
- 31. Related party transactions
- 32. Post balance sheet events
24 Share premium |
||
|
Group and Company |
2009 £’000 |
2008 £’000 |
|
At 1 July |
21,472 |
21,472 |
|
Proceeds from shares issued |
1,722 |
– |
|
Share issue expenses |
(63) |
– |
|
At 30 June |
23,131 |
21,472 |
|
See note 23 above for details of movements in share premium on issue of shares during the year. |
||